Monoclonal antibodies (MoAbs) have transformed the treatment of lymphomas. The first reports of studies using MoAbs appeared 8 years ago, and current therapy for lymphoma patients usually includes treatment with MoAbs once or several times during the course of their disease. This review covers the use of MoAbs in combination with chemotherapy for the treatment of patients with lymphoma. Rituximab, an unconjugated anti-CD20 chimeric antibody, is certainly the most widely used MoAb, but the use of other unconjugated or radiolabeled MoAbs is increasing quickly. MoAbs are effective if used alone, but the duration of effectiveness is limited. Therefore, when MoAbs are used in curative treatment, they are combined with chemotherapy. There are randomized studies demonstrating the benefit of adding MoAbs to the treatment regimen of patients with diffuse large B-cell lymphoma, but results of ongoing studies regarding the benefit in other lymphomas have not been reported. Many questions must be answered before the best setting for MoAbs in the treatment of lymphoma patients can be determined. Int J Hematol. 2002;76:394-400.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.Semin Oncol. 1999;26:66–73.
Grossbard ML, Fidias P, Kinsella J, et al. Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.Brit J Haematol. 1998;102:509–515.
Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131 - Anti-B1 radioimmunotherapy for B-cell lymphoma.J Clin Oncol. 1996;14: 1974–1981.
Witzig TE,White CA,Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin’s lymphoma.J Clin Oncol. 1999;17: 3793–3803.
Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.Blood. 1994;84:2457–2466.
Maloney DG, Grillolopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed nonHodgkin’s lymphoma.J Clin Oncol. 1997;15:3266–3274.
Foran JM, Rohatiner AZS, Coiffier B, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom’s macroglobulinemia, and mantle-cell lymphoma.J Clin Oncol. 1999;17:546–553.
Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma. A multicenter phase II study.Blood. 1998;92:1927–1932.
Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (Idec-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.Cancer Chemother Pharmacol. 1997;12:177–186.
Shan D, Ledbetter JA, Press OW.Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.Blood. 1998; 91:1644–1652.
Shan DM, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.Cancer Immunol Immunother. 2000;48:673–683.
Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B- lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.Blood. 2001;97:1392–1398.
Alas S, Bonavida B.Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/ paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs.Cancer Res. 2001;61:5137–5144.
Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.N Engl J Med. 2001;345:241–247.
Dearden CE, Matutes E, Cazin B, et al. High remission rate in T- cell prolymphocytic leukemia with CAMPATH-1H.Blood. 2001; 98:1721–1726.
McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol. 1998;16:2825–2833.
Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas.J Clin Oncol. 2001;19:3918–3928.
Gordon LI,Witzig TE, Emmanouilides CE, et al. 90Y ibritumomab (Zevalin) in aggressive non-Hodgkin’s lymphoma: analysis of response and toxicity [review].Semin Oncol. 2002;29(suppl 2): 87–92.
Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma.J Clin Oncol. 2002;20:2453–2463.
Foran JM, Rohatiner AZS, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.J Clin Oncol. 2000;18:317–324.
Foran JM, Cunningham D, Coiffier B, et al. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.Ann Oncol. 2000;11:117–121.
The Non-Hodgkin’s Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas. Summary and description of a working formulation for clinical usage.Cancer. 1982;49:2112–2135.
Pan D, Moskowitz CH, Zelenetz AD, Teruya-Feldstein J, Portlock CS. Clinical outcomes of patients treated with rituximab for relapsed or refractory aggressive non-Hodgkin’s lymphoma in the post-transplant setting [abstract].Blood. 2000;96(suppl 1):405a. Abstract 1746.
Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.J Clin Oncol. 1999;17:268–276.
Czuczman MS, Fallon A, Mohr A, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.Semin Oncol. 2002;29:36–40.
Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.J Clin Oncol. 2002;20:1288–1294.
Romaguera JE, Dang NH, Hagemeister FB, et al. Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma (MCL).Blood. 2000;96:733a.
Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma.J Clin Oncol. 2001;19:389–397.
Kewalramani T, Zelenetz A, Bertino J, et al. Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as secondline therapy (SLT) [abstract].Blood. 2001;98(suppl 1):346a. Abstract 1458.
Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma.N Engl J Med. 2002;346:235–242.
The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma.N Engl J Med. 1993;329:987–994.
Hiddemann W, Forstpointner R, Fiedler F, et al. The addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantel cell lymphomas (MCL). Results of a prospective randomized comparison of the German low grade study group (GLSG) [abstract].Blood. 2001; 98(suppl 1):844a. Abstract 3507.
Ghielmini M, Schmite SFH, Cogliatti SB, et al. Maintenance treatment with 2-monthly rituximab after standard weekly X4 rituximab induction significantly improves event-free survival in patients with follicular lymphoma.Ann Oncol. 2002;13(suppl 2):38.
Leonard JP, Coleman M, Matthews JC, et al. Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin’s lymphoma: preliminary response data [abstract].Blood. 2000;96(suppl 1):578a. Abstract 2482.
Witzig TE,White CA,Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma.J Clin Oncol. 1999;17: 3793–3803.
Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of I-131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.Lancet. 1995;346:336–340.
Coiffier B. Diffuse large-cell lymphoma.Curr Op Oncol. 2001;13: 325–334.
About this article
Cite this article
Thieblemont, C., Coiffier, B. Combination of Chemotherapy and Monoclonal Antibodies for the Treatment of Lymphoma. Int J Hematol 76, 394–400 (2002). https://doi.org/10.1007/BF02982804
- Diffuse large cell lymphoma